Exelixis Inc Increase (Decrease) in Accounts Payable and Accrued Liabilities
Exelixis Inc (EXEL) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $18.82 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2016-11-03
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-09-30 was $4.53M.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-06-30 was $8.96M.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-03-31 was $5.33M.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-12-31 was $13.02M.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was -$1.28M.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was -$13.95M, a 260.45% decline from fiscal 2013.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was $8.69M, a 68.79% increase from fiscal 2012.
- Exelixis Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was $5.15M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $13.48M derived: sum of 2 quarters · filed 2016-11-03 | $18.82M 10-Q · filed 2016-11-03 | $31.83M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2016-06-30 | $8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $14.29M 10-Q · filed 2016-08-03 | $27.31M derived: sum of 3 quarters · filed 2016-08-03 | $19.58M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2016-03-31 | $5.33M 10-Q · filed 2016-05-04 | $18.35M derived: sum of 2 quarters · filed 2016-05-04 | $10.62M derived: sum of 3 quarters · filed 2016-11-03 | $10.44M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-12-31 | $13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.29M derived: sum of 2 quarters · filed 2016-11-03 | $5.11M derived: sum of 3 quarters · filed 2016-11-03 | -$1.28M 10-K · filed 2016-02-29 | ||||
| 2015-09-30 | -$7.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$7.91M derived: sum of 2 quarters · filed 2016-11-03 | -$14.29M 10-Q · filed 2016-11-03 | -$162.00K 10-Q · filed 2015-11-10 | -$16.64M derived: sum of 4 quarters · filed 2016-11-03 | |||
| 2015-06-30 | -$181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$6.56M 10-Q · filed 2016-08-03 | $405.00K 10-Q · filed 2015-08-11 | -$8.91M derived: sum of 3 quarters · filed 2016-08-03 | -$15.60M derived: sum of 4 quarters · filed 2016-08-03 | |||
| 2015-03-31 | -$6.38M 10-Q · filed 2016-05-04 | -$3.42M 10-Q · filed 2015-04-30 | -$8.73M derived: sum of 2 quarters · filed 2016-05-04 | -$15.42M derived: sum of 3 quarters · filed 2016-05-04 | -$10.07M derived: sum of 4 quarters · filed 2016-05-04 | |||
| 2014-12-31 | -$2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$9.04M derived: sum of 2 quarters · filed 2016-02-29 | -$3.69M derived: sum of 3 quarters · filed 2016-02-29 | -$13.95M 10-K · filed 2016-02-29 | -$13.21M 10-K · filed 2015-03-02 | |||
| 2014-09-30 | -$6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$1.35M derived: sum of 2 quarters · filed 2015-11-10 | -$11.60M 10-Q · filed 2015-11-10 | -$2.26M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $5.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | -$4.91M 10-Q · filed 2015-08-11 | $4.44M derived: sum of 3 quarters · filed 2016-02-29 | $3.41M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | -$10.25M 10-Q · filed 2015-04-30 | -$911.00K derived: sum of 2 quarters · filed 2016-02-29 | -$1.94M derived: sum of 3 quarters · filed 2016-02-29 | $3.21M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $9.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $8.31M derived: sum of 2 quarters · filed 2016-02-29 | $13.46M derived: sum of 3 quarters · filed 2016-02-29 | $8.69M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $4.12M derived: sum of 2 quarters · filed 2014-11-04 | -$652.00K 10-Q · filed 2014-11-04 | $3.19M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | $5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $379.00K 10-Q · filed 2014-07-31 | $4.22M derived: sum of 3 quarters · filed 2015-03-02 | $7.59M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | -$4.77M 10-Q · filed 2014-05-01 | -$5.47M 10-Q · filed 2013-05-07 | -$928.00K derived: sum of 2 quarters · filed 2015-03-02 | $2.44M derived: sum of 3 quarters · filed 2015-03-02 | $3.12M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $7.21M derived: sum of 2 quarters · filed 2015-03-02 | $7.88M derived: sum of 3 quarters · filed 2015-03-02 | $5.15M 10-K · filed 2015-03-02 | $6.32M 10-K · filed 2013-02-21 | |||
| 2012-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $4.04M derived: sum of 2 quarters · filed 2013-10-30 | $1.31M 10-Q · filed 2013-10-30 | $3.28M 10-Q · filed 2012-11-07 | -$11.27M derived: sum of 4 quarters · filed 2014-02-20 | |||
| 2012-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$2.06M 10-Q · filed 2013-08-06 | $201.00K 10-Q · filed 2012-08-02 | -$14.63M derived: sum of 3 quarters · filed 2014-02-20 | -$17.05M derived: sum of 4 quarters · filed 2014-02-20 | |||
| 2012-03-31 | -$2.74M 10-Q · filed 2013-05-07 | -$15.31M derived: sum of 2 quarters · filed 2014-02-20 | -$17.72M derived: sum of 3 quarters · filed 2014-02-20 | -$21.89M derived: sum of 4 quarters · filed 2014-02-20 | ||||
| 2011-12-31 | -$12.58M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$14.99M derived: sum of 2 quarters · filed 2014-02-20 | -$19.15M derived: sum of 3 quarters · filed 2014-02-20 | -$14.80M 10-K · filed 2014-02-20 | -$5.55M 10-K · filed 2012-02-22 | |||
| 2011-09-30 | -$2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$6.58M derived: sum of 2 quarters · filed 2012-11-07 | -$2.23M 10-Q · filed 2012-11-07 | -$10.46M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-06-30 | -$4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $186.00K 10-Q · filed 2012-08-02 | -$8.05M derived: sum of 3 quarters · filed 2013-02-21 | -$5.63M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-03-31 | $4.35M 10-Q · filed 2012-05-03 | -$3.88M derived: sum of 2 quarters · filed 2013-02-21 | -$1.47M derived: sum of 3 quarters · filed 2013-02-21 | |||||
| 2010-12-31 | -$8.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$5.82M derived: sum of 2 quarters · filed 2013-02-21 | -$9.44M 10-K · filed 2013-02-21 | |||||
| 2010-09-30 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$1.21M 10-Q · filed 2011-10-27 | ||||||
| 2010-06-30 | -$3.63M 10-Q · filed 2011-08-04 | |||||||
| 2009-12-31 | $9.01M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |